漱玉平民大药房为控股子公司福建恒生提供担保进展公告（2026年3月）

漱玉平民大药房连锁股份有限公司为控股子公司福建恒生大药房有限公司提供担保进展公告

公告要点

漱玉平民大药房连锁股份有限公司（以下简称“公司”）为控股子公司福建恒生大药房有限公司（以下简称“福建恒生”）向兴业银行福州分行申请的900万元授信业务，提供540万元连带责任保证担保。
本次担保在公司年度授信及担保额度内，无需另行召开董事会及股东会审议。
公司本次担保后累计对福建恒生的担保余额为540万元，剩余可用担保额度为420万元。
公司及子公司累计对合并报表范围内各级子公司剩余可用担保额度为57,333.50万元。
公司及子公司对外担保总金额为145,412.17万元，占公司最近一期经审计净资产的71.27%；累计对外担保余额为88,078.67万元，占净资产的43.17%。
公司及合并报表范围内各级子公司无逾期担保、无涉诉担保事项，不存在因担保被判决败诉而承担损失的情况。

详细解读

本公告披露，公司董事会和股东会已授权公司及子公司在2026年度向银行等金融机构申请综合授信额度并提供担保，合并报表范围内各级子公司的总担保额度为145,412.17万元，其中对福建恒生担保额度为960万元。

福建恒生近期向兴业银行福州分行申请900万元授信，公司为其提供540万元的连带责任保证担保。本次担保后，公司对福建恒生的担保余额为540万元，仍有420万元担保额度可用。

公司对其他子公司的担保情况也详尽披露，包括为漱玉医药物流（山东）、青岛漱玉平民大药房、东营益生堂药业连锁、福建省民心医药连锁、青岛春天之星医药连锁、烟台漱玉平民大药房等多家子公司合计提供超80,000万元的担保。

被担保公司基本情况

福建恒生成立于2014年，注册资本1,000万元，公司持有其60%股权。
主营业务为药品及健康相关商品的零售。
截至2025年9月30日，资产总额5,376.59万元，负债总额4,662.24万元，银行贷款总额1,601.65万元，流动负债2,900.24万元，净资产714.35万元。
2025年1-9月营业收入5,478.26万元，净利润为-179.48万元，显示公司处于亏损状态。
福建恒生信用状况良好，不属于失信被执行人。

担保合同主要内容

债权人为兴业银行福州分行，保证人为漱玉平民大药房连锁股份有限公司。
担保金额为540万元，方式为连带责任保证。
担保范围包括主合同项下全部债权（本金、利息、违约金、费用等）。
每笔融资履行期限届满起三年为担保期，如展期则担保期顺延。

董事会意见及风险提示

董事会认为本次担保符合公司整体利益，且风险可控，不会损害公司及全体股东，尤其是中小股东利益，也不会影响公司正常运作和业务发展。

对投资者的影响

公司担保规模较大，占净资产比例高（71.27%的额度，43.17%的余额），但未出现逾期和诉讼。
福建恒生为公司控股子公司，公司对其担保比例为60%，其他股东提供同比例担保。
福建恒生经营亏损，需持续关注其经营改善及未来担保风险。
若福建恒生经营状况进一步恶化或出现违约，担保责任将对公司业绩和资金流产生影响。

结论

公司对控股子公司提供担保属于支持其正常经营融资，短期内对公司信誉和资金安全影响有限，但考虑到担保总额及被担保公司亏损情况，投资者需持续关注相关风险。若未来出现担保履约风险或子公司经营恶化，可能对公司股价产生负面影响。

免责声明

本文信息来源于公司公告，仅供投资者参考，不构成任何投资建议。投资者应结合自身情况及市场动态审慎决策。

Progress Announcement: Suyupingmin Pharmacy Provides Guarantee for Subsidiary

Key Points

Suyupingmin Pharmacy Chain Co., Ltd. (“the Company”) is providing a RMB 5.4 million joint guarantee for its controlling subsidiary Fujian Hengsheng Pharmacy Co., Ltd. (“Fujian Hengsheng”) for a RMB 9 million credit facility from Industrial Bank Fuzhou Branch.
The guarantee is within the Company’s previously approved annual quota and does not require further board or shareholder meetings.
After this guarantee, the Company’s total guarantee for Fujian Hengsheng stands at RMB 5.4 million, with RMB 4.2 million quota remaining.
The Company and subsidiaries have a remaining guarantee quota of RMB 573.335 million within the consolidated scope.
Total external guarantees amount to RMB 1,454.1217 million, or 71.27% of audited net assets; total guarantee balance is RMB 880.7867 million, or 43.17% of net assets.
No overdue, litigation, or losses from guarantees within consolidated scope.

Detailed Analysis

The board and shareholders authorized the Company and subsidiaries to apply for comprehensive credit lines and guarantees in 2026, with a total quota of RMB 1,454.1217 million, including RMB 9.6 million for Fujian Hengsheng.

Fujian Hengsheng recently applied for RMB 9 million credit from Industrial Bank Fuzhou branch; the Company provides RMB 5.4 million joint liability guarantee. Post-guarantee, the Company’s guarantee for Fujian Hengsheng totals RMB 5.4 million (RMB 4.2 million available).

The Company’s guarantee for other subsidiaries is detailed, including Suyupingmin Medical Logistics (Shandong) RMB 267.1867 million, Qingdao Suyupingmin RMB 277.8 million, Dongying Yishengtang RMB 27 million, Fujian Minxin RMB 18 million, Qingdao Spring Star RMB 80 million, and others, totaling over RMB 800 million.

Subsidiary Profile

Fujian Hengsheng founded in 2014, RMB 10 million registered capital, 60% held by the Company.
Main business: retail of drugs and health products.
As of Sept 30, 2025: total assets RMB 53.7659 million, liabilities RMB 46.6224 million, bank loans RMB 16.0165 million, current liabilities RMB 29.0024 million, net assets RMB 7.1435 million.
2025 Jan-Sep revenue RMB 54.7826 million, net loss RMB 1.7948 million, showing loss.
Credit status is good, not a dishonest executor.

Guarantee Contract Key Terms

Creditor: Industrial Bank Fuzhou Branch; Guarantor: Suyupingmin Pharmacy Chain Co., Ltd.
Guarantee amount: RMB 5.4 million, joint liability guarantee.
Scope: all debts under main contract (principal, interest, penalties, costs).
Guarantee period: three years after each debt maturity; extensions covered.

Board Opinion & Risk Disclosure

The board considers the guarantee in line with company interests and under control, not harming shareholders, especially minority shareholders, nor affecting normal operations.

Investor Impact

Large guarantee scale (71.27% of net assets quota, 43.17% balance), no overdue or litigation.
Fujian Hengsheng is 60% owned; guarantee is proportional.
Fujian Hengsheng is loss-making; monitor future risk.
If subsidiary worsens or defaults, guarantee liability may impact Company finances and share price.

Conclusion

Guaranteeing the subsidiary supports normal operations and financing, currently limited impact on Company reputation and funds. However, given the scale and subsidiary losses, investors should closely monitor risks. Any future guarantee risk or subsidiary deterioration could negatively affect share price.

Disclaimer

This article is based on Company announcements and is for reference only. It does not constitute investment advice. Investors should make decisions carefully considering their own situation and market dynamics.